Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The lack of non-overlapping toxicities between the two drugs, the ease of all oral drug
administration, and the possibility for antitumor synergy make exploration of this
combination regimen attractive in women with previously treated metastatic breast cancer.
This phase II trial will be performed in collaboration with the Minnie Pearl Cancer Research
Network, a multicenter, community-based clinical trials group.